ED drugs in "supplements" prompt recalls
This article was originally published in The Tan Sheet
Executive Summary
Los Angeles-based Haloteco July 13 recalls Libipower Plus, a product marketed as a dietary supplement that tested positive for tadalafil in an FDA lab analysis. Brea, Calif.-based Opteron 1 Inc., doing business as Nature & Health Co., July 15 recalls products labeled as supplements including LibieXtreme, Y-4ever and Herbal Disiac in retail locations in California, Georgia, Illinois, Ohio and Texas after FDA found tadalafil and analogs of other pharmaceutical ingredients used in Rx erectile dysfunction drugs such as Cialis in the products. Nature & Health Co. also recently recalled its Libimax product (1"The Tan Sheet" May 4, 2009, In Brief)
You may also be interested in...
Libimax supplement a bit too potent
Nature & Health Co. announces a recall of its male enhancement formula after FDA analysis found samples of Libimax contained tadalafil, the active ingredient in Eli Lilly's Rx erectile dysfunction drug Cialis. FDA warns that tadalafil, in conjunction with nitrates found in prescription cholesterol drugs, can cause a dangerous drop in blood pressure. Brea, Calif.-based Nature & Health said April 27 the recalled product was sold in retail stores in California, Georgia, Illinois, Ohio and Texas. FDA has emphasized it will seize adulterated supplement products when firms fail to comply with recall requests (1"The Tan Sheet" July 28, 2008, p. 15)
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.